Earlier treatment with amyloid-targeting therapy linked to better outcomes in Alzheimer’s

CHICAGO — Patients with Alzheimer’s disease on amyloid-targeting therapy had less cognitive decline when their baseline amyloid burden was lower, according to a poster presented at the American Academy of Neurology Annual Meeting.“This is a dataset of people who had at least 6 months of treatment with the donanemab or 12 months of treatment with the lecanemab,” Ahlanna